SunVida
Kilele Health's commitment to supporting heart failure patients began with a 2022 study titled STRONG HF.
This European study conclusively demonstrated that more intensive management of patients after they are discharged from the hospital for heart failure, along with a quicker transition to guideline-directed medical therapy, significantly reduces hospital readmissions and improves overall survival rates.
It was so compelling the study was stopped early.
The challenge is that patients were seen 4 to 5 times more often during the study than what is considered standard practice in the U.S., which is impractical to implement.
At Kilele Health, we tackled this issue by implementing remote patient monitoring. This enables doctors to more efficiently access critical biosensor data, allowing them to make informed decisions, direct their patients to guideline-directed medical therapy and improve patient outcomes
SunVida™ Launch Workflow
How we got here
At Kilele Health, we asked ourselves, “What if we could use Remote Patient Monitoring (RPM) data to replace some of the necessary in-person visits?” This approach would allow patients to achieve results similar to STRONG-HF without overwhelming cardiology practices with additional in-person appointments.
After consulting with dozens of cardiologists and members of heart failure care teams, we concluded that a combination of NT-proBNP, potassium, and creatinine could serve as a viable alternative to in-person patient visits. This is particularly true when these biomarkers are used alongside other RPM data such as heart rate, blood pressure, and fluid/weight measurements.
NT-proBNP
We started building the SunVida™ platform first (SunVida HF-Pro™) by leveraging the most important biomarker referenced in the STRONG -HF study, NT-proBNP. While we could go into great detail about this remarkable molecule, we believe Dr. Ileana Pina* articulates it better in her : [link].
With NT-proBNP as the sole RPM data stream, the number of in-person patient visits is not expected to decrease dramatically. However, we anticipate significant improvements in optimizing the timing and frequency of these encounters, as well as a reduction in hospital readmissions.
*no affiliation with Kilele Heath Inc.
Future of SunVida HF-Pro™
When potassium and creatinine are incorporated into the SunVida HF-Pro™, the need for in-person patient visits and readmission rates will decrease, leading to continued improved outcomes. The next enhancement for the SunVida HF-Pro™ will include monitoring heart rate and tissue oxygen levels. Emerging data also indicates that adding phenylalanine could be beneficial.
The SunVida™ platform offers a remarkable range of sensing capabilities for managing heart failure. By collaborating with other remote patient monitoring (RPM) providers specializing in blood pressure and fluid/weight tracking, we aim to empower cardiology practices to fully utilize RPM technology. This approach aligns with the crucial recommendations set by the European Society of Cardiology for 2024:
“Based upon the results of STRONG-HF, high-intensity care for initiation and rapid up-titration of oral HF therapies and close follow-up in the first 6 weeks after discharge for an acute HF hospitalization is recommended to reduce HF readmission or all-cause death. During the follow-up visits, particular attention should be paid to symptoms and signs of congestion, blood pressure, heart rate, NT-proBNP values, potassium concentrations, and eGFR.”
Contact Us
Are you excited about collaborating with us? We invite you to share your information, and we’ll reach out to you soon. Together, we can bring great ideas to life! We can’t wait to connect and explore the amazing possibilities ahead!